Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 62

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 62
---
 development cost for products development.

The accompanying financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. As of September 30, 2024, the Company had cash of approximately $716 and an accumulated deficit of approximately $20.6 million. The Company has incurred recurring losses, experienced recurring negative operating cash flows, and requires significant cash resources to execute its business plans. The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations. Without additional funding, there is substantial doubt about the Company’s ability to continue as a going concern for the twelve months from the date of these financial statements.

Contractual Obligations

As of September 30, 2024 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Exchange Act.

<div align='center'>45</div>

FINANCIAL STATEMENTS

<div align='center'>REGEN BIOPHARMA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)</div>

|                                                                                                                                   |     | June 30, 2025 |             |   |     | September 30, 2024 |             |   |
|:----------------------------------------------------------------------------------------------------------------------------------|:----|:--------------|------------:|:--|:----|:-------------------|------------:|:--|
|                                                                                                                                   |     | -unaudited    |             |   |     | -as restated       |             |   |
| ASSETS:                                                                                                                           |     |               |             |   |     |                    |             |   |
| Current Assets                                                                                                                    |     |               |             |   |     |                    |             |   |
| Cash                                                                                                                              |     | $             |       1,761 |   |     | $                  |         716 |   |
| Accounts receivable, related party                                                                                                |     |               |     177,147 |   |     |                    |      94,873 |   |
| Prepaid expenses                                                                                                                  |     |               |         200 |   |     |                    |      47,